美罗华联合CHOP方案治疗EBV阳性弥漫大B细胞淋巴瘤的短期随访研究.doc

美罗华联合CHOP方案縮EBV阳性弥漫大B细胞淋 巴瘤究 2018-03-29 10:29:48中国现代医生2018年5期 蔡岗丽 ［摘要］戸的評价美罗华联合CHOP方案(环磷酰胺+表阿儘素+长春新碱+强的松)治疗EBV 阳性弥漫大B细胞淋巴瘤(DLBCL)的效果，并进行短期随访。方法 选取我院2015年3月?2017 年1月收治的120例EBV阳性弥漫大B细胞淋巴瘤患者为本次研究对象，按照治疗方式不同分为对 照组(60例，CHOP方案)与观察组(60例，美罗华+CHOP方案)，对比两组疗效、生存率、无 进展生存率、不良反应。结果 观察组临床治疗总有效率为91.67%(55/60),远高于对照组的75.00% (45/60),数据组间对比差异有统计学意义(P0.05)。观察组生存率96.67% (58/60),对照组 生存率91.67% (55/60),数据组间对比差异无统计学意义(P0.05)；观察组无进展生存率60.00% (36/60),对照组无进展生存率41.67% (25/60),数据组间对比差异有统计学意义(P0.05)。 观察组在治疗过程中未出现恶心呕吐、发热毒副反应，与对照组对比，差异有统计学意义(P0.05), 其余壽副反应数据组间对比差异无统计学意义(P0.05) o结论美罗华+CHOP方案治疗EBV阳 性DLBCL患者能够有效提升其临床效果与无进展生存率，且降低恶心呕吐、发热毒副反应，其余毒 副反应与CHOP方案无明显差异，可临床应用与推广。 ［关键词］美罗华；弥漫大B细胞；淋巴瘤；化学治疗 ［中图分类号］R733.4 ［文献标识码］A ［文章编1673-9701 (2018) 05-0013-04 ［Abstract］ Objective To evaluate the efficacy of rituximab combined with CHOP regimen (cyclophosphamide+epirubicin+vincristine+prednisone) in the treatment of EBV-positive diffuse large B-cell lymphoma and to con duct short-term follow-up. Methods 120 patie nts with EBV-positive diffuse large B cell lymphoma who were treated in our hospital from March 2015 to January 2017 were selected as the study subjects and divided into control group (n二60, CHOP regimen) and observation group (n=60, rituximab+CHOP regimen) , according to different treatment methods. The curative effect, survival rate, progress!on-free survival rate and adverse reactions were compared between the two groups. Results The total effective rate of clinical treatment in observation group was 91.67% (55/60) , which was much higher than that in control group (75.00%, 45/60) . There was significant differenee between two groups (P0.05) . The survival rate of the observation group and the control group was 96.67% (58/60) and 91.67% (55/60), respectively, and there was no significant differenee in the data between the two groups(P0.05)? The progressive-free survival rate was 60.00% (36/60) in the observation group and 41.67% (25/60) in the control group, and the differenee was significant between